View Financial HealthSiegfried Holding 配当と自社株買い配当金 基準チェック /06Siegfried Holding配当を支払う会社であり、現在の利回りは0.49%です。主要情報0.5%配当利回り-0.04%バイバック利回り総株主利回り0.5%将来の配当利回り0.6%配当成長7.9%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向10%最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Mar 27Siegfried Holding AG, Annual General Meeting, Apr 14, 2026Siegfried Holding AG, Annual General Meeting, Apr 14, 2026, at 10:00 W. Europe Standard Time.お知らせ • Feb 21Siegfried Announces Management ChangesSiegfried will consolidate the Chief Operating Officer roles currently split between Drug Substances and Drug Products into one position. In this context, Henrik Krüpper will be stepping down from his responsibilities as Chief Operating Officer Drug Substances to pursue opportunities outside the company, effective March 1, 2026. Stefan Randl has been appointed ad interim Chief Operating Officer Drug Substances in addition to his role as Chief Scientific Officer until a Chief Operating Officer is appointed.お知らせ • Feb 09Siegfried Holding AG to Report First Half, 2026 Results on Aug 21, 2026Siegfried Holding AG announced that they will report first half, 2026 results on Aug 21, 2026お知らせ • Jan 28+ 2 more updatesSiegfried Holding AG (SWX:SFZN) entered into a binding agreement to acquire Noramco, Inc. from SK Capital Partners, LP and The Noramco Group.Siegfried Holding AG (SWX:SFZN) entered into a binding agreement to acquire Noramco, Inc. from SK Capital Partners, LP and The Noramco Group on January 27, 2026. Given Siegfried’s strong balance sheet, the acquisition will be financed through existing and new debt instruments. In separate related transactions, Siegfried Holding AG also signed binding agreements to acquire Purisys and Extractas Bioscience. Following the close of the transaction, SK Capital will retain ownership of Halo Pharmaceuticals. The transaction is subject to customary closing conditions and regulatory approvals. The expected completion of the transaction is in late 2026. The valuation of the acquired business is below 10 times Enterprise Value / EBITDA. Jefferies Financial Group Inc., RBC Capital Markets, LLC and Rothschild & Co US Inc. acted as financial advisors for Noramco, Inc. Kirkland & Ellis LLP acted as legal advisor for Noramco. The team of Cravath, Swaine & Moore LLP led by G.J. Ligelis Jr., Daniel J. Cerqueira and Ryan J. Wichtowski, Lauren Angelilli, Eric W. Hilfers, David J. Kappos, Carys J. Webb, Margaret T. Segall, Matthew Morreale, Joyce Law, Brian M. Budnick, Crawford Rundlett and Jesús Saracho acted as legal advisor for Siegfried Holding AG.お知らせ • Sep 04Siegfried Holding AG to Report Fiscal Year 2025 Results on Feb 20, 2026Siegfried Holding AG announced that they will report fiscal year 2025 results on Feb 20, 2026お知らせ • Mar 24Siegfried Holding AG, Annual General Meeting, Apr 10, 2025Siegfried Holding AG, Annual General Meeting, Apr 10, 2025, at 10:00 W. Europe Standard Time.お知らせ • Jan 30Siegfried Holding AG to Report First Half, 2025 Results on Aug 21, 2025Siegfried Holding AG announced that they will report first half, 2025 results on Aug 21, 2025お知らせ • Aug 22Siegfried Holding AG to Report Fiscal Year 2024 Results on Feb 18, 2025Siegfried Holding AG announced that they will report fiscal year 2024 results on Feb 18, 2025お知らせ • Aug 20Siegfried Holding AG to Report First Half, 2024 Results on Aug 22, 2024Siegfried Holding AG announced that they will report first half, 2024 results on Aug 22, 2024お知らせ • Jul 02Siegfried Holding AG (SWX:SFZN) completed the acquisition of early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc.Siegfried Holding AG (SWX:SFZN) agreed to acquire early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc. on June 12, 2024. The acquisition is financed from existing funds. the transaction is subject to customary closing conditions and is expected to close by July 1, 2024.Siegfried Holding AG (SWX:SFZN) completed the acquisition of early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc on july 1, 2024. As part of the acquisition, all projects at the Grafton site have been transferred to Siegfried and the Siegfried Acceleration Hub will continue to fulfill all commitments to its existing customers.お知らせ • Aug 15+ 1 more updateSiegfried Holding AG to Report Fiscal Year 2023 Results on Feb 20, 2024Siegfried Holding AG announced that they will report fiscal year 2023 results on Feb 20, 2024お知らせ • May 18Siegfried Announces Executive ChangesSiegfried announces two changes to its Executive Committee: Irene Wosgien, currently serving as Chief Operating Officer Drug Substances (COO DS), will take over the global responsibility as Chief Human Resources Officer (CHRO) from Arnoud Middel who will leave Siegfried end of June 2023. Henrik Krupper, currently CEO of HCS Group, will join Siegfried to become the new COO DS. Irene Wosgien will take over as CHRO on 1 July 2023 while Arnoud Middel will assist her during the transition and will continue to support key HR projects until the end of the year. Henrik Krupper will assume his role on 1 November 2023 at the latest. Until then and starting on 1 July 2023, Marcel Imwinkelried will lead the DS technical operations organization in parallel to his regular role as Chief Operating Officer Drug Products. Both, Irene Wosgien and Henrik Krupper, will serve as members of Siegfried's Executive Committee. Arnoud Middel joined Siegfried in 2011 and since then has successfully built a professional global HR function which has been instrumental to Siegfried's organizational development and strong growth over the years. After 12 years with the company, he decided to leave Siegfried in order to pursue private ventures and prepare them next chapters of his career. Henrik Krupper (52, German citizen) holds a diploma (Dipl.-Ing.) in mechanical engineering with a specialization in process engineering from the Technical University (RWTH) Aachen (Germany). After completing his studies, he started his career at Th. Goldschmidt AG as site excellence and production manager followed by positions with increasing operational and managerial responsibilities at Evonik Industries AG (formerly Degussa AG), City Solar AG, Q-Cells SE and Soltecture GmbH. In 2012, he joined HCS Group, an international specialty chemicals company based in Germany, as Managing Director and Chief Commercial Officer and was appointed to his current role of Chief Executive Officer of the company in 2019.お知らせ • May 06Siegfried Holding AG (SWX:SFZN) acquired 95% stake in DiNAMIQS from DiNAQOR AG.Siegfried Holding AG (SWX:SFZN) acquired 95% stake in DiNAMIQS from DiNAQOR AG on May 4, 2023.Siegfried Holding AG (SWX:SFZN) completed the acquisition of 95% stake in DiNAMIQS from DiNAQOR AG on May 4, 2023.お知らせ • Aug 20Siegfried Holding AG to Report Fiscal Year 2022 Results on Feb 22, 2023Siegfried Holding AG announced that they will report fiscal year 2022 results on Feb 22, 2023決済の安定と成長配当データの取得安定した配当: SGFE.FはUS市場で注目すべき配当金を支払っていないため、支払いが安定しているかどうかを確認する必要はありません。増加する配当: SGFE.FはUS市場で注目すべき配当金を支払っていないため、支払額が増加しているかどうかを確認する必要はありません。配当利回り対市場Siegfried Holding 配当利回り対市場SGFE.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SGFE.F)0.5%市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Life Sciences)0.7%アナリスト予想 (SGFE.F) (最長3年)0.6%注目すべき配当: SGFE.Fの配当金 ( 0.49% ) はUS市場の配当金支払者の下位 25% ( 1.4% ) と比べると目立ったものではありません。高配当: SGFE.Fの配当金 ( 0.49% ) はUS市場の配当金支払者の上位 25% ( 4.18% ) と比較すると低いです。株主への利益配当収益カバレッジ: SGFE.F US市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: SGFE.Fは配当金を支払っていますが、同社にはフリーキャッシュフローがありません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 06:54終値2026/03/12 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Siegfried Holding AG 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Justin Steven SmithBernsteinPatrick Andrew WoodBofA Global ResearchVineet AgrawalCitigroup Inc13 その他のアナリストを表示
お知らせ • Mar 27Siegfried Holding AG, Annual General Meeting, Apr 14, 2026Siegfried Holding AG, Annual General Meeting, Apr 14, 2026, at 10:00 W. Europe Standard Time.
お知らせ • Feb 21Siegfried Announces Management ChangesSiegfried will consolidate the Chief Operating Officer roles currently split between Drug Substances and Drug Products into one position. In this context, Henrik Krüpper will be stepping down from his responsibilities as Chief Operating Officer Drug Substances to pursue opportunities outside the company, effective March 1, 2026. Stefan Randl has been appointed ad interim Chief Operating Officer Drug Substances in addition to his role as Chief Scientific Officer until a Chief Operating Officer is appointed.
お知らせ • Feb 09Siegfried Holding AG to Report First Half, 2026 Results on Aug 21, 2026Siegfried Holding AG announced that they will report first half, 2026 results on Aug 21, 2026
お知らせ • Jan 28+ 2 more updatesSiegfried Holding AG (SWX:SFZN) entered into a binding agreement to acquire Noramco, Inc. from SK Capital Partners, LP and The Noramco Group.Siegfried Holding AG (SWX:SFZN) entered into a binding agreement to acquire Noramco, Inc. from SK Capital Partners, LP and The Noramco Group on January 27, 2026. Given Siegfried’s strong balance sheet, the acquisition will be financed through existing and new debt instruments. In separate related transactions, Siegfried Holding AG also signed binding agreements to acquire Purisys and Extractas Bioscience. Following the close of the transaction, SK Capital will retain ownership of Halo Pharmaceuticals. The transaction is subject to customary closing conditions and regulatory approvals. The expected completion of the transaction is in late 2026. The valuation of the acquired business is below 10 times Enterprise Value / EBITDA. Jefferies Financial Group Inc., RBC Capital Markets, LLC and Rothschild & Co US Inc. acted as financial advisors for Noramco, Inc. Kirkland & Ellis LLP acted as legal advisor for Noramco. The team of Cravath, Swaine & Moore LLP led by G.J. Ligelis Jr., Daniel J. Cerqueira and Ryan J. Wichtowski, Lauren Angelilli, Eric W. Hilfers, David J. Kappos, Carys J. Webb, Margaret T. Segall, Matthew Morreale, Joyce Law, Brian M. Budnick, Crawford Rundlett and Jesús Saracho acted as legal advisor for Siegfried Holding AG.
お知らせ • Sep 04Siegfried Holding AG to Report Fiscal Year 2025 Results on Feb 20, 2026Siegfried Holding AG announced that they will report fiscal year 2025 results on Feb 20, 2026
お知らせ • Mar 24Siegfried Holding AG, Annual General Meeting, Apr 10, 2025Siegfried Holding AG, Annual General Meeting, Apr 10, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Jan 30Siegfried Holding AG to Report First Half, 2025 Results on Aug 21, 2025Siegfried Holding AG announced that they will report first half, 2025 results on Aug 21, 2025
お知らせ • Aug 22Siegfried Holding AG to Report Fiscal Year 2024 Results on Feb 18, 2025Siegfried Holding AG announced that they will report fiscal year 2024 results on Feb 18, 2025
お知らせ • Aug 20Siegfried Holding AG to Report First Half, 2024 Results on Aug 22, 2024Siegfried Holding AG announced that they will report first half, 2024 results on Aug 22, 2024
お知らせ • Jul 02Siegfried Holding AG (SWX:SFZN) completed the acquisition of early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc.Siegfried Holding AG (SWX:SFZN) agreed to acquire early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc. on June 12, 2024. The acquisition is financed from existing funds. the transaction is subject to customary closing conditions and is expected to close by July 1, 2024.Siegfried Holding AG (SWX:SFZN) completed the acquisition of early-phase CDMO site in Grafton, Wisconsin from Curia Global, Inc on july 1, 2024. As part of the acquisition, all projects at the Grafton site have been transferred to Siegfried and the Siegfried Acceleration Hub will continue to fulfill all commitments to its existing customers.
お知らせ • Aug 15+ 1 more updateSiegfried Holding AG to Report Fiscal Year 2023 Results on Feb 20, 2024Siegfried Holding AG announced that they will report fiscal year 2023 results on Feb 20, 2024
お知らせ • May 18Siegfried Announces Executive ChangesSiegfried announces two changes to its Executive Committee: Irene Wosgien, currently serving as Chief Operating Officer Drug Substances (COO DS), will take over the global responsibility as Chief Human Resources Officer (CHRO) from Arnoud Middel who will leave Siegfried end of June 2023. Henrik Krupper, currently CEO of HCS Group, will join Siegfried to become the new COO DS. Irene Wosgien will take over as CHRO on 1 July 2023 while Arnoud Middel will assist her during the transition and will continue to support key HR projects until the end of the year. Henrik Krupper will assume his role on 1 November 2023 at the latest. Until then and starting on 1 July 2023, Marcel Imwinkelried will lead the DS technical operations organization in parallel to his regular role as Chief Operating Officer Drug Products. Both, Irene Wosgien and Henrik Krupper, will serve as members of Siegfried's Executive Committee. Arnoud Middel joined Siegfried in 2011 and since then has successfully built a professional global HR function which has been instrumental to Siegfried's organizational development and strong growth over the years. After 12 years with the company, he decided to leave Siegfried in order to pursue private ventures and prepare them next chapters of his career. Henrik Krupper (52, German citizen) holds a diploma (Dipl.-Ing.) in mechanical engineering with a specialization in process engineering from the Technical University (RWTH) Aachen (Germany). After completing his studies, he started his career at Th. Goldschmidt AG as site excellence and production manager followed by positions with increasing operational and managerial responsibilities at Evonik Industries AG (formerly Degussa AG), City Solar AG, Q-Cells SE and Soltecture GmbH. In 2012, he joined HCS Group, an international specialty chemicals company based in Germany, as Managing Director and Chief Commercial Officer and was appointed to his current role of Chief Executive Officer of the company in 2019.
お知らせ • May 06Siegfried Holding AG (SWX:SFZN) acquired 95% stake in DiNAMIQS from DiNAQOR AG.Siegfried Holding AG (SWX:SFZN) acquired 95% stake in DiNAMIQS from DiNAQOR AG on May 4, 2023.Siegfried Holding AG (SWX:SFZN) completed the acquisition of 95% stake in DiNAMIQS from DiNAQOR AG on May 4, 2023.
お知らせ • Aug 20Siegfried Holding AG to Report Fiscal Year 2022 Results on Feb 22, 2023Siegfried Holding AG announced that they will report fiscal year 2022 results on Feb 22, 2023